EyePoint Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
/ 
Frequently asked questions
To buy EyePoint Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for EyePoint Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for EyePoint Pharmaceuticals Inc. is EYPT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
EyePoint Pharmaceuticals Inc. has its primary listing on NASDAQ. You can trade EyePoint Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, EyePoint Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include EyePoint Pharmaceuticals Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like EyePoint Pharmaceuticals Inc..